

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: EHLICH <i>et al.</i> Appl. No.: 10/594,177 (U.S. National Phase of PCT/EP2004/007529) §371 date: August 13, 2007 For: Secreted Proteins as Markers for Cell Differentiation	Confirmation No.: 5698 Art Unit: 1633 Examiner: HIRIYANNA, Kelaginamane T. Atty. Docket: 2590.0050002/EJH/SAC
---	--

**Request for Corrected Patent Application Publication
Under 37 C.F.R. § 1.221(b)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop: PGPUB

Sir:

Pursuant to 37 C.F.R. § 1.221(b), Applicants respectfully request that the captioned publication be republished to correct material errors by the USPTO. Specifically, the following corrections are requested:

Corrections Requested in Publication
On Face Page at section (76) Inventors, please add "Heribert Bohlen, Köln (DE)" and "Silke Schwengberg, Düren (DE)" below "Andreas Ehlich, Mechernich (DE)".

Support for the requested corrections in the publication can be found on the face page in the corresponding published PCT application, WO 2005/005662 A2.

Copies of the affected pages of the publication are enclosed with the requested corrections noted. Republication of the captioned publication to correct material mistakes made by the USPTO is believed proper and issuance thereof is respectfully requested.

This request is being made within two months from the date of publication of the captioned patent application. No fee is believed to be due. The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: March 1, 2010

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

1077910_1.doc



US 20090328243A1

(19) United States

(12) Patent Application Publication
Ehlich

(10) Pub. No.: US 2009/0328243 A1
(43) Pub. Date: Dec. 31, 2009

(54) SECRETED PROTEINS AS MARKERS FOR
CELL DIFFERENTIATION

Publication Classification

(51) Int. Cl.
A01K 67/027 (2006.01)
C12Q 1/02 (2006.01)
C12Q 1/42 (2006.01)
C12Q 1/40 (2006.01)
C07H 21/04 (2006.01)
C12N 5/06 (2006.01)
A01N 1/00 (2006.01)
C40B 40/02 (2006.01)
C40B 60/12 (2006.01)
C12Q 1/68 (2006.01)
C12N 15/00 (2006.01)
A61K 31/19 (2006.01)

(76) Inventor: **Andreas Ehlich**, Mechernich (DE)
Herrmannstrasse, 21a (08)
Correspondence Address: **Silke Schaefer**, D-51144
STERNE, KESSLER, GOLDSTEIN & FOX P.L.
L.C.
1100 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005 (US)

(52) U.S. Cl. 800/13; 435/29; 435/21; 435/22;
536/24.2; 435/325; 435/1.1; 506/14; 506/39;
435/6; 435/320.1; 514/557

(21) Appl. No.: 10/594,177

(22) PCT Filed: Jul. 8, 2004

(86) PCT No.: PCT/EP04/07529

(57) ABSTRACT

§ 371 (c)(1),
(2), (4) Date: Aug. 13, 2007


Provided are means and methods for *in vitro* and *in vivo* detection of chemically induced effects on embryonic development and differentiation for the purpose of embryotoxicity/teratogenicity screening as well as for the identification of pharmaceuticals such as growth and tissue promoting factors based on differentiating pluripotent embryonic stem (ES) cells. The assays are based on the use of transgenic ES cells and non-human animals comprising such ES cells or derivatives thereof, wherein said ES cells are characterized by the differentiation-dependent expression of a secreted reporter protein; in particular secreted embryonic alkaline phosphatase (SEAP).

Related U.S. Application Data

(60) Provisional application No. 60/485,462, filed on Jul. 8, 2003.

(30) Foreign Application Priority Data

Jul. 8, 2003 (EP) 03015400.0



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/005662 A2

(51) International Patent Classification⁷:

C12Q 1/68

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2004/007529

(22) International Filing Date: 8 July 2004 (08.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03015400.9 8 July 2003 (08.07.2003) EP
60/485,462 8 July 2003 (08.07.2003) US

(71) Applicant (for all designated States except US): AXIO-GENESIS AG [DE/DE]; Joseph-Stelzmann-Str. 50, 50931 Köln (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EHLICH, Andreas [DE/DE]; Johannesweg 35, 53894 Mechernich (DE). BOHLEN, Heribert [DE/DE]; Auerstrasse 4, 50733 Köln (DE). SCHWENGBERG, Silke [DE/DE]; Dampfmühlenstr. 107, 52355 Düren (DE).

(74) Agent: STEINECKE, Peter; Müller, Fottner, Steinecke, P.O. Box 31 01 40, 80102 Munich (DE).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SECRETED PROTEINS AS MARKERS FOR CELL DIFFERENTIATION

(57) Abstract: Provided are means and methods for in vitro and in vivo detection of chemically induced effects on embryonic development and differentiation for the purpose of embryotoxicity/teratogenicity screening as well as for the identification of pharmaceuticals such as growth and tissue promoting factors based on differentiating pluripotent embryonic stem (ES) cells. The assays are based on the use of transgenic ES cells and non-human animals comprising such ES cells or derivatives thereof, wherein said ES cells are characterized by the differentiation-dependent expression of a secreted reporter protein; in particular secreted embryonic alkaline phosphatase (SEAP).

WO 2005/005662 A2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

EHLICH *et al.*

Appl. No.: 10/594,177

Filed: July 8, 2004

For: **Secreted Proteins as Markers for
Cell Differentiation**

Confirmation No.: 5698

Art Unit: 1633

Examiner: HIRIYANNA, Kelaginamane T.

Atty. Docket: 2590.0050002/EJH/SAC

Request for Corrected Official Filing Receipt

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop Missing Parts

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested: **Under "Applicant(s)", please insert --Heribert Bohlen, Köln, GERMANY-- and also insert --Silke Schwengberg, Düren, GERMANY-- below Andreas Ehlich, Mechernich, GERMANY.** In support of the above request, a marked-up copy of the instant Official Filing Receipt is enclosed to show the corrections. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: March 1, 2010

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
1078683_1.DOC



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE RECD	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
10/594,177	08/13/2007	1632	3079	2590.0050002/EJH/SAC	54	2

CONFIRMATION NO. 5698

26111
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005

FILING RECEIPT



OC000000037843201

Date Mailed: 09/18/2009

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Investor -- Andreas Ehlich, Mechernich, GERMANY;

Power of Attorney: -- *Heribert Bohlen, Köln, Germany*--

John Jones--44174

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP04/07529 07/08/2004

which claims benefit of 60/485,462 07/08/2003

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 03015400.0 07/08/2003

If Required, Foreign Filing License Granted: 09/16/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 10/594,177**

Projected Publication Date: 12/31/2009

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Secreted proteins as markers for cell differentiation

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).